P21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Flak, Magdalena B ^a   Connell, Claire M ^a,b   Chelala, Claude ^a   Archibald, Kyra ^a   Salako, Michael A ^a   Pirlo, Katrina J ^a   Lockley, Michelle ^a   Wheatley, Sally P ^b   Balkwill, Frances R ^a   McNeish, Iain A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D; E1A PROTEIN; ONCOLYTIC ADENOVIRUS; PROTEIN P21; SMALL INTERFERING RNA; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CELL STRAIN HCT116; CELL TRANSFORMATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; SENSITIVITY ANALYSIS; SIMIAN VIRUS 40; TREATMENT OUTCOME; TUMOR XENOGRAFT; VIRUS INFECTIVITY; VIRUS REPLICATION; WESTERN BLOTTING; ADENOVIRUS; GENE SILENCING; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PH; PHYSIOLOGY; VIROLOGY;

ADENOVIRIDAE; ONYX;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CYCLIN D; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROGEN-ION CONCENTRATION; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; S PHASE;

EID: 77954882437     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-175     Document Type: Article

References (53)

1. Jones N, Shenk T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci USA 1979, 76:3665-3669. 10.1073/pnas.76.8.3665, 383893, 291030.
2. Fattaey AR, Harlow E, Helin K. Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes. Mol Cell Biol 1993, 13:7267-7277. 364797, 8246949.
3. Ikeda MA, Nevins JR. Identification of distinct roles for separate E1A domains in disruption of E2F complexes. Mol Cell Biol 1993, 13:7029-7035. 364764, 8413292.
4. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 2008, 27:3081-3090. 10.1038/sj.onc.1210977, 2493060, 18071311.
5. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Med 2000, 6:1134-1139. 10.1038/80474, 11017145.
6. Lockley M, Fernandez M, Wang Y, Li NF, Conroy SE, Lemoine NR, McNeish IA. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with adenovirus wild-type, bioluminescence monitoring and intraperitoneal delivery in icodextrin. Cancer Res 2006, 66:989-998. 10.1158/0008-5472.CAN-05-2691, 16424034.
7. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112. 10.1016/S1535-6108(02)00102-2, 12204530.
8. Connell CM, Wheatley SP, McNeish IA. Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res 2008, 69:7923-7931.
9. D'Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 2004, 10:8132-8141. 10.1158/1078-0432.CCR-04-0886, 15623586.
10. Yaginuma Y, Hayashi H, Kawai K, Kurakane T, Saitoh Y, Kitamura S, Sengoku K, Ishikawa M. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines. Exp Cell Res 1997, 233:233-239. 10.1006/excr.1997.3560, 9194486.
11. Li NF, Broad S, Lu YJ, Yang JS, Watson R, Hagemann T, Wilbanks G, Jacobs I, Balkwill F, Dafou D, Gayther SA. Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Prolif 2007, 40:780-794. 10.1111/j.1365-2184.2007.00462.x, 17877616.
12. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001, 21:5644-5657. 10.1128/MCB.21.16.5644-5657.2001, 87285, 11463845.
13. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT, Douglas JT. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002, 38:1917-1926. 10.1016/S0959-8049(02)00131-4, 12204675.
14. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, Hermann M, Widschwendter M, Bergelson JM, Marth C. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 2002, 9:1093-1100. 10.1038/sj.gt.3301775, 12140737.
15. Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in Vitro. Clin Cancer Res 2000, 6:4323-4333.
16. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001, 75:8772-8780. 10.1128/JVI.75.18.8772-8780.2001, 115122, 11507222.
17. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. Embo J 1997, 16:2294-2306. 10.1093/emboj/16.9.2294, 1169831, 9171344.
18. Herbst RS, Pelletier M, Boczko EM, Babiss LE. The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function. J Virol 1990, 64:161-172. 249075, 2136708.
19. Bruder JT, Hearing P. Cooperative binding of EF-1A to the E1A enhancer region mediates synergistic effects on E1A transcription during adenovirus infection. J Virol 1991, 65:5084-5087. 248974, 1651424.
20. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997, 272:12738-12746. 10.1074/jbc.272.19.12738, 9139732.
21. Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E, Nishimura S, Taya Y. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. Embo J 1996, 15:7060-7069. 452531, 9003781.
22. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996, 271:8313-8320. 10.1074/jbc.271.33.19637, 8626527.
23. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998, 18:753-761. 108786, 9447971.
24. Inoue Y, Kitagawa M, Taya Y. Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. Embo J 2007, 26:2083-2093. 10.1038/sj.emboj.7601652, 1852778, 17380128.
25. Nakanishi M, Kaneko Y, Matsushime H, Ikeda K. Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein. Biochem Biophys Res Commun 1999, 263:35-40. 10.1006/bbrc.1999.1296, 10486249.
26. Hengst L, Gopfert U, Lashuel HA, Reed SI. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). Genes Dev 1998, 12:3882-3888. 10.1101/gad.12.24.3882, 317274, 9869641.
27. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997, 11:847-862. 10.1101/gad.11.7.847, 9106657.
28. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J 1999, 18:1571-1583. 10.1093/emboj/18.6.1571, 1171245, 10075928.
29. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512. 10.1101/gad.13.12.1501, 10385618.
30. Hale TK, Contreras A, Morrison AJ, Herrera RE. Phosphorylation of the linker histone H1 by CDK regulates its binding to HP1alpha. Mol Cell 2006, 22:693-699. 10.1016/j.molcel.2006.04.016, 16762841.
31. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biol 2001, 3:245-252. 10.1038/35060032, 11231573.
32. Dash BC, El-Deiry WS. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 2005, 25:3364-3387. 10.1128/MCB.25.8.3364-3387.2005, 1069593, 15798220.
33. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371:534-537. 10.1038/371534a0, 7935768.
34. Najafi SM, Li Z, Makino K, Shao R, Hung MC. The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells. Biochem Biophys Res Commun 2003, 305:1099-1104. 10.1016/S0006-291X(03)00905-7, 12767945.
35. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, Branton PE. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J Virol 2001, 75:699-709. 10.1128/JVI.75.2.699-709.2001, 113966, 11134283.
36. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 2006, 14:768-778. 10.1016/j.ymthe.2006.07.009, 16990052.
37. Bosetti F, Bell JM, Manickam P. Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res Bull 2005, 65:331-338. 10.1016/j.brainresbull.2005.01.004, 15811599.
38. Lee MH, Hong I, Kim M, Lee BH, Kim JH, Kang KS, Kim HL, Yoon BI, Chung H, Kong G, Lee MO. Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol Appl Pharmacol 2007, 220:45-59. 10.1016/j.taap.2006.12.016, 17292431.
39. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Viscomi C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008, 143:520-531.
40. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008, 30:61-72. 10.1016/j.molcel.2008.02.030, 2373760, 18406327.
41. Keblusek P, Dorsman JC, Teunisse AF, Teunissen H, van der Eb AJ, Zantema A. The adenoviral E1A oncoproteins interfere with the growth-inhibiting effect of the cdk-inhibitor p21(CIP1/WAF1). J Gen Virol 1999, 80:381-390.
42. Shiina M, Lacher MD, Christian C, Korn WM. RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Ther 2009, 16:810-9. 10.1038/cgt.2009.29, 19407849.
43. Fueyo J, Gomez-Manzano C, Alemany R, Lee P, McDonnell T, Mitlianga P, Shi Y-X, VA L, Yung W, Kyritsis A. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19:2-12. 10.1038/sj.onc.1203251, 10644974.
44. Tollefson AE, Scaria A, Ying B, Wold WS. Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells. J Virol 2003, 77:7764-7778. 10.1128/JVI.77.14.7764-7778.2003, 161948, 12829816.
45. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 1996, 220:152-162. 10.1006/viro.1996.0295, 8659107.
46. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLoS Med 2008, 5:e232. 10.1371/journal.pmed.0050232, 2592352,2592352, 19053170.
47. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004, 10:5168-5177. 10.1158/1078-0432.CCR-03-0751, 15297421.
48. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88:2584-2589. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5, 10861437.
49. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999, 85:669-677. 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F, 10091740.
50. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000, 36:357-361. 10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2, 10949993.
51. Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A, Capuzzi D, Kovatich AJ. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Hum Pathol 2000, 31:698-704. 10.1053/hupa.2000.7641, 10872663.
52. Li NF, Wilbanks G, Balkwill F, Jacobs IJ, Dafou D, Gayther SA. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab Invest 2004, 84:923-931. 10.1038/labinvest.3700093, 15077121.
53. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004, 20:3705-3706. 10.1093/bioinformatics/bth449, 15297296.